Abstract
Visual alterations under classic psychedelics can include rich phenomenological accounts of eyes-closed imagery. Bottom-up connectivity of the visual pathway underpins sensory perception, with top-down connectivity enhanced during intentional imagery. Preclinical evidence suggests agonism of the 5-HT2A receptor may reduce synaptic gain to produce psychedelic induced-imagery. However, this has not been investigated in humans. To infer the directed connectivity changes to visual sensory connectivity underlying psychedelic visual imagery, we applied dynamic causal modelling to the resting state eyes-closed functional MRI scans of healthy adults after administration of psilocybin or placebo. The model included early visual regions, fusiform gyrus, intraparietal sulcus, and inferior frontal gyrus. We observed a pattern of increased self-inhibition of both early visual and higher visual-associative regions under psilocybin. The increased self-inhibition was associated with behavioural measures of complex and elementary imagery, and a pattern of reduced excitation and inhibition from visual-associative regions to earlier visual areas. The results are consistent with preclinical findings and inform our understanding of clinical hallucinations and perception, and suggest deprivation of sensory activity may amplify endogenous associative neural activity. The findings inform the neurobiology of psychedelic-induced changes to sensory connectivity and the neural mechanisms associated with closed-eyes visual imagery.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT03736980
Funding Statement
Heffter Research Institute (Grant No. 1- 190420) Swiss Neuromatrix Foundation (Grant No. 2016-0111), Swiss National Science Foundation under the framework of Neuron Cofund (Grant No. 01EW1908), Slovenian Research Agency (ARRS) (Grant Nos. J7-8275, J7-6829,Council Discovery Early Career Research Award Fellowship DE170100128 (to AR), Australian Research Council Discovery Project grant DP200100757 (AR), Australian National Health and Medical Research Council Investigator grant 1194910 (AR), Wellcome Centre for Human Neuroimaging supported by core funding from Wellcome grant 203147/Z/16/Z (AR)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The data analysed in this paper were collected as part of a previous study (registered at ClinicalTrials.gov (NCT03736980)), which is reported in (Preller et al., 2020, doi: 10.1016/j.biopsych.2019.12.027) and was approved by the Cantonal Ethics Committee of Zurich.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵+ Joint Senior Authors
Data Availability
All data produced in the present study are available upon reasonable request to the authors
